FDA records identify Karl Storz Endoscopy-America, Inc. as the applicant behind PMA P050027, covering the Karl Storz Photodynamic Diagnostic D-Light C (PDD) System. The original approval, dated 28 May 2010, describes a combination diagnostic imaging system reviewed with the optical imaging drug Cysview (hexaminolevulinate hydrochloride) for intravesical solution. The device carries generic name "Light source system, diagnostic endoscopic," product code OAY, and device class 3, with the advisory committee recorded as Gastroenterology, Urology. The manufacturer's instruction manual lists the system's components, including rigid Hopkins II PDD telescopes, the D-Light-C light source, a PDD camera head, and Telecam SL and Tricam SL units. [1][2][5][9]

The approved system and its labeled scope

The approval statement for P050027 covers the D-Light C (PDD) System in combination with Cysview for photodynamic blue-light cystoscopy, as an adjunct to white light cystoscopy for detection of non-muscle invasive papillary cancer of the bladder in patients suspected or known to have the lesion on the basis of a prior cystoscopy. The FDA summary of safety and effectiveness records that the device, as a component of a combination diagnostic imaging system, was presented to the Oncologic Drugs Advisory Committee for the Center for Drug Evaluation and Research on 17 December 2009. The summary directs users to the PDD Operator Manual for system instructions and to the Cysview package insert for use with the drug. [2][5]

The manufacturer's instruction manual identifies the product as the Photodynamic Diagnostic D-Light C (PDD) System and organizes its appendices around the rigid Hopkins II PDD telescopes, the D-Light-C light source, the PDD camera head, and the Telecam SL and Tricam SL instruction manuals, plus a fluid light cable package insert. The manual carries a 2004 copyright notice for Karl Storz Endoscopy-America, Inc. at 2151 E. Grand Avenue, El Segundo, California. [9]

Supplement activity in the filing record

A 30-day notice supplement, P050027/S038, was received 24 September 2026 and decided 14 October 2026 with decision code OK30. The supplement type is recorded as a 30-Day Notice and the reason as Process Change - Manufacturer/Sterilizer/Packager/Supplier. Its approval order statement addresses reducing the curing time of the adhesive used at the distal end of rigid endoscopes 27005AIA, 27005BIA, 27005CIA, and 27005FIA from 60 minutes to 30 minutes. The expedited review flag is recorded as N. [1]

The linked collection for this applicant contains two PMA records as of 20 November 2026: one original approval and one 30-day notice. The smaller record sample of two entries shows the same split, with one OK30 and one APPR. These counts describe the linked filings retrieved at that date and are not a measure of total company portfolio, sales, or safety performance. [1][2]

Applicant identity and published documentation

The applicant name on both PMA records is Karl Storz Endoscopy-America, Inc., with a filing address of 2151 E. Grand Ave., El Segundo, CA 90245. The same address appears in the manufacturer's instruction manual. FDA filing addresses are not treated here as a verified corporate headquarters, and no parent, affiliate, or brand relationship is confirmed by these records. [1][2][9]

The FDA premarket approval database pages for P050027 and several of its supplements present standard navigation and contact material rather than substantive device detail in the retrieved text. Product-level information in this profile therefore rests on the PMA records and the manufacturer's published summary and instruction manual. [3][4][6][7][8][10]